Key Takeaways for CVS Health Stock as of August 2026
- YTD Run: CVS Health stock is up 18% since early January, a pace that annualizes to 32%, though shares trade well below their early-August high.
- Post-Earnings Slide: CVS Health stock fell as much as 10% intraday and closed down 5.8% on August 5 after a first look at 2027 profit undercut a raised 2026 forecast.
- Street Positioning: Coverage carries 18 buys, 6 outperforms, and 3 holds, and the mean target of $116 sits 23% above the current $95 price for CVS Health stock.
- Model Upside: TIKR’s mid-case model targets $132 for CVS Health stock by December 2030, implying a 40% total return, or 8% annualized.
CVS Health Stock’s 18% Rally Runs Into a Rough Post-Earnings Reset
CVS Health stock (CVS) has climbed 18% since early January, a run that annualizes to 32%. But the shares now trade meaningfully below the roughly $110 high they touched in late July, and the reason traces to a single session. CVS reported second-quarter results on August 5 that beat estimates on nearly every line, then watched its own stock fall 5.8% to $98, after sliding as much as 10% intraday.
The quarter itself was not the problem. CVS raised its 2026 adjusted EPS guidance to a range of $7.90 to $8.10, up 60 cents on both ends from its prior $7.30 to $7.50 view, and lifted its cash-flow outlook to at least $11.5 billion. What rattled the market was CVS’s first look at 2027: an adjusted profit floor of at least $8.44 per share, a number that implied slower growth than the size of the second-quarter beat suggested it should. CFO Brian Newman tried to frame that figure as conservative rather than weak on the Q2 earnings call: “While we would not normally comment on 2027 consensus this early in the year, an outlook of at least $8.44, consistent with current consensus, appears reasonable at this juncture.” Investors read it as a ceiling. CVS Health stock has kept drifting since, closing at $95 on August 12.
Caremark, the company’s pharmacy benefit manager, sits at the center of that caution. Executive Prem Shah told analysts the unit is “trending to a retention rate that’s slightly lower than our historical performance” heading into 2027, with 340B drug-pricing rules continuing to squeeze margins on discounted sales. That is the tension defining CVS Health stock right now. A business that just beat estimates for a seventh straight quarter is being priced by a market more worried about next year’s client losses than impressed by this year’s numbers.
CVS Health Stock’s Target Keeps Climbing as the Price Gap Reopens
Analysts covering CVS Health stock carry 18 buys, 6 outperforms, and 3 holds as of August 12, with no underperform or sell ratings on the board. The mean target sits at $116, 23% above the current $95 price.
That gap has not been static. The mean target has risen every quarter since June 2025, climbing from $80 to $116 as CVS Health stock round-tripped from the high $60s to over $100 and back.
As recently as June 30, the gap had nearly closed entirely, with the target at $106 sitting just 2% above a price of $103. Then the Street pushed the target another 10% higher after the Q2 beat while the stock fell, reopening the spread to 23%.
The low end of the range tells a similar story: the most conservative target held at $79 for four straight quarters before jumping to $103 in the latest reading, meaning even the Street’s biggest skeptic has now been forced above where the stock traded for most of the past year.
TIKR Values CVS Health Stock at $132, Pricing In a 2027 Snapback
TIKR’s mid-case model values CVS Health stock at $132 by December 2030, implying a 40% total return from the current price of $95, or 8% annualized over roughly 4.4 years.
An 8% annualized pace outruns the low-single-digit growth typically priced into a defensive healthcare payer, a gap that only widens the longer CVS Health stock trades below where the Street already sees it.
The model’s case leans on the same divide separating analysts from the market. Coverage has kept raising targets through the 2027 caution, effectively betting that Caremark’s flagged retention dip and 340B pressure prove temporary rather than structural. A stock priced at $95 against a Street mean of $116 and a model target of $132 is a market still discounting a profit outlook management itself called reasonable.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
